REPLACED BY ART 34 AMDT

Claims:

1. Use of a compound other than 9-(azabicyclo[2.2.2]octane-3-one)-6-chloro-9H-purine having the ability to restore the apoptosis-inducing function of mutant p53 proteins, which compound is selected from compounds having a structure according to the formula I



wherein:

R1 is hydrogen or a methylene group, which can be double bonded, as indicated by the broken line, or single bonded and linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and;

A is an oxygen-containing moiety, either consisting of an oxygen atom being double bonded, as indicated by the broken line, or a benzoyloxy group, with the proviso that when A is a benzoyloxy group, then R1 is hydrogen,

for the preparation of a medicament for treating mutant p53 mediated diseases.

2. The use of claim 1, wherein the compound is selected from 2-(adenine-9-methylene)-3-quinuclidinone, 2-methylene-3-quinuclidinone, 2-(-2-amino-3-chloro-5-trifluoromethyl-1-methylaniline)-3-quinuclidinone, 2-(6-trifluoromethyl-4-chlorobenzimidazole-1-methylene)-3-quinuclidinone, 2-(6-methoxypurine-9-methylene)-3-quinuclidinone, 2-(8-azaadenine-9-methylene)-3-quinuclidinone, 1-azabicyclo [2.2.2]oct-3-yl benzoate, 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, or 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone.

3. The use of claim 1 or 2, wherein the compound is selected from compounds having the structure of the general formula I'



wherein

R1 is a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and, more preferably R1 is a methylene group linked to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue.

4. Use of a compound having the ability to restore the apoptosis-inducing function of mutant p53 proteins, which compound is selected from compounds having the structure of the general formula II



wherein

R2 is chosen from the group consisting of hydrogen, methyl, or benzyl,

for the preparation of a medicament for treating mutant p53 mediated diseases.

5. The use of claim 4, wherein the compound is 2-ethylene-4(3 H)-quinazolinone.

6. The use of anyone of the claims 1-5 together with a pharmaceutically acceptable carrier, diluent and/or excipient.

7. The use of anyone of the claims 1-6, wherein the mutant p53 mediated disease is cancer.

8. A method of treating a mutant p53 mediated disease, comprising administrating to a mammal in need thereof a pharmaceutically efficient amount of a compound selected from compounds having a structure according to the formula I



wherein:

R1 is hydrogen or a methylene group, which can be double bonded, as indicated by the broken line, or single bonded and linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and;

A is an oxygen-containing moiety, either consisting of an oxygen atom being double bonded, as indicated by the broken line, or a benzoyloxy group, with the proviso that when A is a benzoyloxy group, then R1 is hydrogen; or

a compound selected from compounds having the structure of the general formula II



wherein

R2 is chosen from the group consisting of hydrogen, methyl, or benzyl.

9. The method of claim 8, wherein the mutant p53 mediated disease is cancer.